Douglas White

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 10

Top Venues

Rheumatology and therapy

Rheumatology international

PeerJ

International journal of environmental research and public health

University of Auckland School of Medicine

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Auckland School of Medicine Mar 01 2014

New Zealand

Honorary Clinical Lecturer :: Waikato Clinical School

Waikato District Health Board Feb 02 2010

New Zealand

Rheumatologist :: Rheumatology

Publications

Lars Erik Kristensen, Mauro Keiserman, Kim A Papp, Leslie McCasland, Douglas White, Kyle Carter, Ralph Lippe, Huzefa Photowala, Leonidas Drogaris, Ahmed M Soliman, Michael Chen, Byron Padilla, Frank Behrens
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Lars Erik Kristensen, Mauro Keiserman, Kim A Papp, Leslie McCasland, Douglas White, Kyle Carter, Ralph Lippe, Huzefa Photowala, Leonidas Drogaris, Ahmed M Soliman, Michael Chen, Byron Padilla, Frank Behrens
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Lars Erik Kristensen, Mauro Keiserman, Kim A Papp, Leslie McCasland, Douglas White, Kyle Carter, Ralph Lippe, Huzefa Photowala, Leonidas Drogaris, Ahmed M Soliman, Michael Chen, Byron Padilla, Frank Behrens
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial. Rheumatology and therapy (2024)
Lars Erik Kristensen, Mauro Keiserman, Kim A Papp, Leslie McCasland, Douglas White, Kyle Carter, Ralph Lippe, Huzefa Photowala, Leonidas Drogaris, Ahmed M Soliman, Michael Chen, Byron Padilla, Frank Behrens
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Lars Erik Kristensen, Mauro Keiserman, Kim A Papp, Leslie McCasland, Douglas White, Kyle Carter, Ralph Lippe, Huzefa Photowala, Leonidas Drogaris, Ahmed M Soliman, Michael Chen, Byron Padilla, Frank Behrens
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Chunhuan Lao, Philippa Van Dantzig, Douglas White, Kannaiyan Rabindranath, Donna Foxall, Ross Lawrenson
Prevalence and outcomes of end-stage kidney disease in patients with systemic lupus erythematous: a population-based study. Rheumatology international (2023)
Grace Johnstone, Gareth J Treharne, Benjamin D Fletcher, Roisin S M Hegarty, Douglas White, Andrew A Harrison, Simon M Stebbings
Mental health and quality of life for people with rheumatoid arthritis or ankylosing spondylitis in Aotearoa New Zealand following the COVID-19 national lockdown. Rheumatology international 41 (10) (2021)
Chunhuan Lao, David Lees, Sandeep Patel, Douglas White, Ross Lawrenson
Length of Hospital Stay for Osteoarthritic Primary Hip and Knee Replacement Surgeries in New Zealand. International journal of environmental research and public health 16 (23) (2019)
Rebecca L Roberts, Mary C Wallace, Andrew A Harrison, Douglas White, Nicola Dalbeth, Lisa K Stamp, Daniel Ching, John Highton, Tony R Merriman, Philip C Robinson, Matthew A Brown, Simon M Stebbings
Association of Crohn's disease-related chromosome 1q32 with ankylosing spondylitis is independent of bowel symptoms and faecal calprotectin. PeerJ 6 (2018)
Clement Ooi, Kamal K Solanki, Chunhuan Lao, Chris Frampton, Douglas White
Mortality in the Waikato Hospital Systemic Sclerosis Cohort. International journal of rheumatic diseases 21 (1) (2017)

Douglas White.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Douglas White